Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00669955
Other study ID # PYLHp07-01
Secondary ID
Status Completed
Phase Phase 3
First received April 29, 2008
Last updated August 3, 2010
Start date June 2008
Est. completion date August 2009

Study information

Verified date August 2010
Source Axcan Pharma
Contact n/a
Is FDA regulated No
Health authority Germany: Federal Institute for Drugs and Medical DevicesUnited Kingdom: National Health ServiceSpain: Ethics CommitteeSpain: Ministry of HealthPoland: Ministry of HealthIreland: Irish Medicines BoardItaly: National Bioethics CommitteeFrance: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis)Netherlands: Medicines Evaluation Board (MEB)
Study type Interventional

Clinical Trial Summary

This study aims at evaluating efficacy and safety of quadruple therapy (bismuth, metronidazole, tetracycline and omeprazole: OBMT) vs triple therapy (amoxicillin, clarithromycin and omeprazole: OAC) in H. Pylori eradication. It is hypothesized that quadruple therapy will be comparable in efficacy to triple therapy. Subjects with confirmed H. pylori positive status will be randomized to one of the treatments described above. At week 6 and 10 follow-up visits, a urea breath test(UBT) will be performed to confirm eradication.


Description:

The study will include three phases: screening, treatment and follow-up. Screening: this phase will last a maximum of 30 days and subjects eligibility will be evaluated after informed consent signature. Endoscopy and Urea Breath test will be performed in addition to the baseline routine evaluations.

Treatment: Subjects assigned to OAC will be treated for 7 days. Those assigned to Pylera will be treated for 10 days. A randomization visit will take place on Day 0 and an end-of-treatment visit will take place between day 8 and 14.

Follow-up: includes two visits. approximately one and two months post-treatment. Eradication of H. Pylori will be confirmed through UBT, and resistance will be evaluated in case of treatment failure. These subjects will undergo an endoscopy.


Recruitment information / eligibility

Status Completed
Enrollment 440
Est. completion date August 2009
Est. primary completion date July 2009
Accepts healthy volunteers No
Gender Both
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Positive H. Pylori status;

- Presence of upper gastro-intestinal symptoms;

- Mental and legal ability to sign informed consent.

Exclusion Criteria:

- Previous surgery of the GI tract;

- Clinically significant impairment of renal or hepatic function;

- Severe unstable cardiovascular, pulmonary or endocrine disease;

- Barrett's oesophagus or high-grade dysplasia;

- Dysphagia or vomiting as major symptoms.

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Drug:
Omeprazole, amoxicillin, clarithromycin
Triple therapy given for 7 days at a dose of omeprazole 20 mg BID, amoxicillin 500 mg 2 capsules BID, and clarithromycin 500 mg 1 tablet BID
Pylera (Bismuth subcitrate potassium, metronidazole, tetracycline) given in combination with omeprazole
Pylera is a three in one capsule containing bismuth subcitrate potassium 120 mg, metronidazole 125 mg and tetracycline 125 mg given as 3 capsules QID, with omeprazole 20 mg BID.

Locations

Country Name City State
United Kingdom Dr. I. Orpen Bath

Sponsors (1)

Lead Sponsor Collaborator
Axcan Pharma

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Primary Helicobacter Pylori Eradication Confirmed by Urea Breath Test H. pylori Eradication defined as a negative C13-UBT (urea breath test) result at both Week 6 and Week 10 follow-up visits. Week 6 and week 10 follow-up visits No
Secondary Number of Patients Experiencing Treatment Emergent Adverse Events. A treatment-emergent adverse event is defined as an event not present prior to exposure to the study medication or any event already present that worsens in either intensity or frequency following exposure to study medication up to 30 days after study discontinuation.
All safety analysis based on the safety population.
at the end of treatment (day 8-14), week 6 and wek 10 follow-up visits. Yes
Secondary H. Pylori Eradication and Presence or Past History of Peptic Ulcers Eradication rates in the subset of patients with peptic ulcer (current or past history) at baseline are reported based on the per protocol population. Eradication must be confirmed at week 6 and week 10 by a negative Urea Breath Test conducted within the allocated windows. Week 6 and week 10 follow-up visits No
Secondary Clarithromycin Resistance Eradication rates in subset of patients infected with a bacterial strain confirmed as resistant to clarithromycin at baseline. Resistance to clarithromycin defined as Minimum Inhibitory Concentration (MIC) of 1 ug/ml and above Measured at baseline No
Secondary Metronidazole Resistance Eradication rates in subset of patients infected with a bacterial strain confirmed as resistant to metronidazole at baseline. Resistance to metronidazole defined as Minimum Inhibitory Concentration (MIC) above 8 ug/ml Measured at baseline No
Secondary Overall Compliance to Study Medications Overall compliance: number of capsules dispensed - number of capsules returned/Number of prescribed capsules X 100. Percentages based on safety population At the end of the treatment phase (days 8-14) No
Secondary Number of Patients With Bismuth Plasma Concentrations Above the Toxic Level Tolerability of OBMT with respect to plasma bismuth concentrations: number of patients with bismuth concentrations above the toxic level (50 ug per liter) Baseline (both arms), end of treatment (Day 11-14) and end of study (Day 70) OBMT arm only Yes
See also
  Status Clinical Trial Phase
Completed NCT00723502 - Efficacy and Safety Study of Finafloxacin Used in Helicobacter Pylori Infected Patients Phase 2
Recruiting NCT03365609 - A Comparison of Four Different Treatment Regimens of Helicobacter Pylori in Chinese Children N/A
Completed NCT00005496 - Inflammation, Infection, and Future Cardiovascular Risk N/A
Completed NCT01219764 - A Trial of Standard vs Half Dose Rabeprazole, Clarithromycin, Metronidazole and Amoxicillin in the Treatment of Helicobacter Pylori Infection Phase 4
Completed NCT00216450 - Study of the Safety and Effectiveness of Rabeprazole in Treatment of Helicobacter Pylori Infection in Adults. Phase 4
Completed NCT00212225 - Risk Factors for Gastric Disease in Pediatric Helicobacter Pylori (H. Pylori) N/A
Completed NCT00083291 - Helicobacter Pylori and Dry Eye N/A
Not yet recruiting NCT04652284 - Effectiveness of Rifabutin for Treatment of Helicobacter Pylori Phase 3
Completed NCT02449941 - Helicobacter Pylori and Proton Pump Inhibitor N/A
Completed NCT02395458 - Efficacy on Helicobacter Pylori Eradication With Two Antibiotic Regimens Phase 4
Completed NCT00194688 - Breath Ammonia Method for H. Pylori Detection: Phase II Phase 2
Not yet recruiting NCT02126722 - Endofaster Test for Helicobacter Pylori Detection in Patients on Proton Pump Inhibitor Therapy N/A
Active, not recruiting NCT01133951 - Helicobacter Pylori Eradication to Prevent Gastric Cancer N/A
Completed NCT00816140 - Levofloxacin Versus Clarithromycin Triple Therapy in First-Line Treatment for Helicobacter Pylori Eradication Phase 4
Completed NCT00490386 - Helicobacter Pylori and Acute Alcohol Induced Pancreatitis N/A
Withdrawn NCT02645201 - The Effect of Probiotic Combination on Helicobacter Pylori Infection in Children N/A
Terminated NCT00664209 - Treating H. Pylori in Parkinson's Patients With Motor Fluctuations Phase 3
Completed NCT01922505 - Eradication Rates of Helicobacter Pylori and Its Affecting Factors Phase 4
Completed NCT01792700 - Long-term Follow up Helicobacter Pylori Reinfection Rate After Second-Line Treatment: Bismuth-Containing Quadruple Therapy Versus Moxifloxacin-Based Triple Therapy Phase 4
Completed NCT02970110 - Specimen Collection Study for H. Pylori Testing